Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Double-Blind, Sponsor-Open, Placebo-Controlled, First-In-Human Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Ascending Doses of CVL-936 In Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Double-Blind, Sponsor-Open, Placebo-Controlled, First-In-Human Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Ascending Doses of CVL-936 In Healthy Subjects

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CVL 936 (Primary)
  • Indications Substance-related disorders
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Cerevel Therapeutics

Most Recent Events

  • 18 Jun 2020 Status changed from active, no longer recruiting to discontinued.
  • 19 Mar 2020 Status changed from recruiting to active, no longer recruiting.
  • 30 Jan 2020 According to an Cerevel Therapeutics media release, results of this trial which will generate key safety, tolerability and pharmacokinetic data to inform further clinical development of CVL-936 in patients.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top